IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1810 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded422    
    Comments [Add]    
    Cited by others 4    

Recommend this journal


Year : 2004  |  Volume : 36  |  Issue : 3  |  Page : 133-139

Glycoprotein IIb/IIIa receptor and its inhibition: A platelet-directed therapeutic strategy

Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, Gujarat, India

Correspondence Address:
R K Goyal
Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, Gujarat
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Platelets play a key role in atherosclerosis, thrombosis and acute coronary syndromes. Drugs that dissolve blood clot (thrombolytic agents) and that prevent clot propagation (antiplatelet and anticoagulant agents) are used to treat a broad array of cardiovascular diseases. Therapeutic manipulation of platelet function has focused principally on the use of aspirin which has proved effective in many clinical situations, despite its relatively weak antiplatelet action as compared to newer agents like ticlopidine, clopidogrel and more recently, platelet glycoprotein (GP) IIb/IIIa receptor inhibitors. The platelet GP IIb/IIIa receptor has been identified as a pivotal mediator of platelet aggregation, making it a logical target for the control of the platelet response to vascular injury. The primary mechanism of GP IIb/IIIa antagonists is the inhibition of the final common pathway of platelet aggregation: fibrinogen binding to the GP IIb/IIIa complex. Various antagonists of the GP IIb/IIIa receptor are currently receiving considerable attention and are being investigated for various clinical settings including angina, myocardial infarction and interventional cardiology.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow